
Paul S Haber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1876305/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction, 2022, 117, 382-391.	1.7	22
2	Daily experiences of hangover severity and food consumption in young adults. British Journal of Health Psychology, 2022, 27, 468-483.	1.9	1
3	Variability in insulin pharmacokinetics following high-dose insulin therapy. Clinical Toxicology, 2022, 60, 389-391.	0.8	2
4	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	1.8	33
5	Support for Aboriginal health services in reducing harms from alcohol: 2â€year service provision outcomes in a cluster randomized trial. Addiction, 2022, 117, 796-803.	1.7	6
6	Effects of service-wide support on regularity of alcohol screening of clients in Australian Aboriginal and Torres Strait Islander Community Controlled Health Services: a cluster randomised trial. Addiction Science & Clinical Practice, 2022, 17, 13.	1.2	0
7	Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence. Frontiers in Global Women S Health, 2022, 3, 807269.	1.1	4
8	Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. Sports Medicine - Open, 2022, 8, 27.	1.3	10
9	More than three times as many Indigenous Australian clients at risk from drinking could be supported if clinicians used AUDIT-C instead of unstructured assessments. Addiction Science & Clinical Practice, 2022, 17, 23.	1.2	3
10	A pilot study of a text message and online brief contact intervention following self-harm or a suicide attempt: A mixed methods evaluation. General Hospital Psychiatry, 2022, 76, 1-2.	1.2	2
11	The evaluation of the role of technology in the pathways to comorbidity care implementation project to improve management of comorbid substance use and mental disorders. Journal of Multimorbidity and Comorbidity, 2022, 12, 263355652210969.	0.8	3
12	Alcohol use disorder and the gut. Addiction, 2021, 116, 658-667.	1.7	19
13	Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology, 2021, 238, 1291-1302.	1.5	19
14	Psychosocial Interventions for Reducing Suicidal Behaviour and Alcohol Consumption in Patients With Alcohol Problems: A Systematic Review of Randomized Controlled Trials. Alcohol and Alcoholism, 2021, 56, 17-27.	0.9	7
15	Randomised controlled trial of integrated cognitive behavioural treatment and motivational enhancement for comorbid social anxiety and alcohol use disorders. Australian and New Zealand Journal of Psychiatry, 2021, 55, 207-220.	1.3	8
16	Genomeâ€wide Association Study and Metaâ€analysis on Alcoholâ€Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology, 2021, 73, 1920-1931.	3.6	54
17	How intoxicated are you? Investigating self and observer intoxication ratings in relation to blood alcohol concentration. Drug and Alcohol Review, 2021, 40, 1173-1177.	1.1	4
18	What are people saying on social networking sites about the Australian alcohol consumption guidelines?. Medical Journal of Australia, 2021, 214, 105.	0.8	2

#	Article	IF	CITATIONS
19	Support can increase use of the AUDIT in Australian Aboriginal Community Controlled Health Services: a cluster randomized trial. Addiction, 2021, 116, 2304-2315.	1.7	8
20	A systematic review of evidence-based practice implementation in drug and alcohol settings: applying the consolidated framework for implementation research framework. Implementation Science, 2021, 16, 22.	2.5	20
21	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opinion on Pharmacotherapy, 2021, 22, 1291-1303.	0.9	18
22	Should we be using eâ€vouchers to compensate research participants? Acceptability among opioid agonist treatment clients. Drug and Alcohol Review, 2021, 40, 1356-1357.	1.1	2
23	High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology, 2021, 46, 28-36.	0.3	10
24	Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. JAMA Network Open, 2021, 4, e219041.	2.8	55
25	Are bottle shops using Twitter to increase advertising or encourage drinking during COVIDâ€19?. Australian and New Zealand Journal of Public Health, 2021, 45, 391-393.	0.8	0
26	Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. Drug and Alcohol Dependence, 2021, 227, 108959.	1.6	33
27	Developing a model of care for substance use in pregnancy and parenting services, Sydney, Australia: Service provider perspectives. Journal of Substance Abuse Treatment, 2021, 131, 108420.	1.5	2
28	The role of clinical supervision in implementing evidence-based practice for managing comorbidity. Clinical Supervisor, The, 2021, 40, 158-177.	1.1	7
29	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. American Journal of Gastroenterology, 2021, 116, 106-115.	0.2	25
30	Implementation of a Multi-Modal Training Program for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings: Pathways to Comorbidity Care (PCC). Journal of Dual Diagnosis, 2021, 17, 304-312.	0.7	6
31	Treatment of alcohol problems: current status and future directions. Medical Journal of Australia, 2021, 215, 315-316.	0.8	3
32	Gastrointestinal Disorders Related to Alcohol and Other Drug Use. , 2021, , 1077-1097.		2
33	Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study. Addiction Biology, 2020, 25, e12702.	1.4	6
34	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre―and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	1.0	39
35	Brain N-Acetyl Aspartate and associations with cognitive impairment in alcohol dependent patients. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 111-117.	0.8	7
36	Designing, implementing and evaluating the overdose response with takeâ€home naloxone model of care: An evaluation of client outcomes and perspectives. Drug and Alcohol Review, 2020, 39, 55-65.	1.1	12

#	Article	IF	CITATIONS
37	Australian treatment outcome study: protocol for the 18–20-year follow-up of a prospective longitudinal cohort examining the natural history of heroin dependence and associated mortality, psychiatric and physical health, and health service use. BMJ Open, 2020, 10, e039226.	0.8	5
38	Alcohol use disorder and circulating cytokines: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2020, 89, 501-512.	2.0	44
39	Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review. BMC Family Practice, 2020, 21, 260.	2.9	9
40	Genetic Polymorphisms on OPRM1, DRD2, DRD4, and COMT in Young Adults: Lack of Association With Alcohol Consumption. Frontiers in Psychiatry, 2020, 11, 549429.	1.3	4
41	Implementation of evidence-based practice for alcohol and substance use disorders: protocol for systematic review. Systematic Reviews, 2020, 9, 25.	2.5	13
42	Baclofen modulates cardiovascular responses to appetitive cues in treatmentâ€seeking alcohol use disorder individuals. Human Psychopharmacology, 2020, 35, e2722.	0.7	7
43	Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC/cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV) Journal of Clinical Oncology, 2020, 38, 12008-12008.	0.8	0
44	Comment on pill testing review. Internal Medicine Journal, 2020, 50, 1596-1597.	0.5	2
45	GABAB Receptors and Alcohol Use Disorders: Clinical Studies. Current Topics in Behavioral Neurosciences, 2020, , 195-212.	0.8	6
46	Development of a joint mental-health and drug health assessment unit and short-stay unit. Australasian Psychiatry, 2019, 27, 374-377.	0.4	9
47	Cue Exposure Therapy for Alcohol Use Disorders: What Can Be Learned from Exposure Therapy for Anxiety Disorders?. Substance Use and Misuse, 2019, 54, 2053-2063.	0.7	25
48	Vitamin B ₁₂ supplementation futile for preventing demyelination in ongoing nitrous oxide misuse. Medical Journal of Australia, 2019, 211, 428.	0.8	15
49	Detection of Δ ⁹ THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two pointâ€ofâ€collection testing devices. Drug Testing and Analysis, 2019, 11, 1486-1497.	1.6	32
50	A pilot study of escape, avoidance, and approach behaviors in treated alcohol-dependent males. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 601-614.	0.8	3
51	Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment. Substance Use and Misuse, 2019, 54, 1589-1598.	0.7	14
52	Longâ€ŧerm safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outâ€patients with opioid use disorder. Addiction, 2019, 114, 1416-1426.	1.7	75
53	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 2019, 236, 2713-2724.	1.5	130
54	Identification of smoking status in the Census is needed, but what about the healthcare system?. Australian and New Zealand Journal of Public Health, 2019, 43, 96.	0.8	0

#	Article	IF	CITATIONS
55	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. Alcohol and Alcoholism, 2019, 54, 272-278.	0.9	9
56	Systematic Reviews of Mindfulness and Acceptance and Commitment Therapy for Alcohol Use Disorder: Should we be using Third Wave Therapies?. Alcohol and Alcoholism, 2019, 54, 159-166.	0.9	44
57	118â€Case series: subacute combined degeneration of the spinal cord in vitamin B12-replete recreational nitrous oxide abusers. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A38.2-A39.	0.9	0
58	Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for a cluster randomised controlled trial. BMJ Open, 2019, 9, e030909.	0.8	12
59	Evidence-based models of care for the treatment of alcohol use disorder in primary health care settings: protocol for systematic review. Systematic Reviews, 2019, 8, 275.	2.5	3
60	Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease. Alcohol and Alcoholism, 2019, 54, 38-46.	0.9	11
61	A Review of Baclofen Overdoses in Australia: Calls to a Poisons Information Centre and a Case Series. Alcohol and Alcoholism, 2019, 54, 73-78.	0.9	10
62	Impact of acutely behavioural disturbed patients in the emergency department: A prospective observational study. EMA - Emergency Medicine Australasia, 2019, 31, 387-392.	0.5	28
63	Examining Perceived Stress, Childhood Trauma and Interpersonal Trauma in Individuals With Drug Addiction. Psychological Reports, 2019, 122, 433-450.	0.9	55
64	â€~Nurse specialling': Direct nursing observation in the emergency department compared to other wards of an urban teaching hospital in Sydney. Australasian Psychiatry, 2018, 26, 276-280.	0.4	4
65	Translating Evidence-Based Practice for Managing Comorbid Substance Use and Mental Illness Using a Multimodal Training Package. Journal of Dual Diagnosis, 2018, 14, 111-119.	0.7	13
66	Characteristics of Suicide Attempters and Ideators in a Clinical Sample of Substance Users. Substance Use and Misuse, 2018, 53, 1811-1818.	0.7	2
67	Vertical transmission of hepatitis C: Testing and healthâ€care engagement. Journal of Paediatrics and Child Health, 2018, 54, 647-652.	0.4	6
68	Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry, 2018, 212, 362-369.	1.7	87
69	Biased and less sensitive: A gamified approach to delay discounting in heroin addiction. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 139-150.	0.8	27
70	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol, 2018, 66, 1-7.	0.8	13
71	Evaluation of a novel method for the analysis of alcohol biomarkers: Ethyl glucuronide, ethyl sulfate and phosphatidylethanol. Alcohol, 2018, 67, 7-13.	0.8	33

Applications and Challenges for the Use of Phosphatidylethanol Testing in Liver Disease Patients (Mini) Tj ETQq0.0 rgBT /Overlock 10 T $_{1.4}^{72}$

#	Article	IF	CITATIONS
73	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry,the, 2018, 5, 957-960.	3.7	94
74	Baclofen Response in Alcohol Dependent Patients Concurrently Receiving Antidepressants: Secondary Analysis From the BacALD Study. Frontiers in Psychiatry, 2018, 9, 576.	1.3	5
75	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. Drug and Alcohol Review, 2018, 37, 887-896.	1.1	5
76	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open, 2018, 8, e020745.	0.8	16
77	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. Current Addiction Reports, 2018, 5, 287-296.	1.6	7
78	Moderation of baclofen response by a GABA _B receptor polymorphism: results from the BacALD randomized controlled trial. Addiction, 2018, 113, 2205-2213.	1.7	19
79	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. Expert Opinion on Investigational Drugs, 2018, 27, 667-675.	1.9	20
80	Harnessing advances in computer simulation to inform policy and planning to reduce alcohol-related harms. International Journal of Public Health, 2018, 63, 537-546.	1.0	21
81	Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials, 2018, 19, 443.	0.7	5
82	Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking. Frontiers in Psychiatry, 2018, 9, 412.	1.3	9
83	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Frontiers in Psychiatry, 2018, 9, 708.	1.3	47
84	Psychostimulant-related health service demand in an inner-city hospital, 2012–2015. Public Health Research and Practice, 2018, 28, .	0.7	1
85	Intolerance of uncertainty and conditioned place preference in opioid addiction. PeerJ, 2018, 6, e4775.	0.9	9
86	Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV) Journal of Clinical Oncology, 2018, 36, TPS10128-TPS10128.	0.8	0
87	Alcohol Related Harm: Knowledge Assessment of Medical and Nursing Staff in a General Hospital. , 2018, 55, 32-36.		1
88	Preliminary results of a controlled educational intervention on alcohol related harm among medical students with a 12-month follow-up. , 2018, 55, 37-39.		0
89	Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. Journal of Substance Abuse Treatment, 2017, 74, 23-25.	1.5	17
90	Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opinion on Investigational Drugs, 2017, 26, 563-578.	1.9	97

#	Article	IF	CITATIONS
91	Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug and Alcohol Dependence, 2017, 181, 132-139.	1.6	27
92	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 2017, 11, 10-18.	1.4	9
93	Reward and punishment-based compound cue learning and generalization in opiate dependency. Experimental Brain Research, 2017, 235, 3153-3162.	0.7	3
94	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. Mental Health and Physical Activity, 2017, 13, 57-67.	0.9	5
95	Learning and generalization from reward and punishment in opioid addiction. Behavioural Brain Research, 2017, 317, 122-131.	1.2	27
96	Intolerance of uncertainty in opioid dependency – Relationship with trait anxiety and impulsivity. PLoS ONE, 2017, 12, e0181955.	1.1	28
97	A Mobile Text Message Intervention to Reduce Repeat Suicidal Episodes: Design and Development of Reconnecting After a Suicide Attempt (RAFT). JMIR Mental Health, 2017, 4, e56.	1.7	27
98	Alcoholic Liver Disease in Asia, Europe, and North America. Gastroenterology, 2016, 150, 1786-1797.	0.6	133
99	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. Drug and Alcohol Dependence, 2016, 166, 254-257.	1.6	34
100	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 425-434.	0.6	6
101	Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study. Transplantation Direct, 2016, 2, e104.	0.8	19
102	The impact of an automatic syringe dispensing machine in innerâ€city Sydney, Australia: No evidence of a â€~honeyâ€pot' effect. Drug and Alcohol Review, 2016, 35, 637-643.	1.1	8
103	The Reluctance of Liver Transplant Participants with Alcoholic Liver Disease to Participate in Treatment for Their Alcohol Use Disorder: An Issue of Treatment Matching?. Alcoholism Treatment Quarterly, 2016, 34, 233-251.	0.5	7
104	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction, 2016, 111, 311-319.	1.7	63
105	Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia. International Journal of Drug Policy, 2016, 27, 121-126.	1.6	11
106	Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. Journal of Clinical Virology, 2016, 74, 66-72.	1.6	11
107	Probabilistic reward- and punishment-based learning in opioid addiction: Experimental and computational data. Behavioural Brain Research, 2016, 296, 240-248.	1.2	51
16.5	Alashalwas disardars langat The 2016 287 088 008		

108 Alcohol use disorders. Lancet, The, 2016, 387, 988-998.

6.3 277

#	Article	IF	CITATIONS
109	The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates. Public Health Research and Practice, 2016, 26, .	0.7	5
110	Brief Report: Genetics of Alcoholic Cirrhosis— <scp>G</scp> enom <scp>ALC</scp> Multinational Study. Alcoholism: Clinical and Experimental Research, 2015, 39, 836-842.	1.4	29
111	Circulating Lipids Are Associated with Alcoholic Liver Cirrhosis and Represent Potential Biomarkers for Risk Assessment. PLoS ONE, 2015, 10, e0130346.	1.1	33
112	Alcopops, taxation and harm: a segmented time series analysis of emergency department presentations. BMC Public Health, 2015, 15, 468.	1.2	35
113	Harmonizing Post-Market Surveillance of Prescription Drug Misuse: A Systematic Review of Observational Studies Using Routinely Collected Data (2000–2013). Drug Safety, 2015, 38, 553-564.	1.4	15
114	Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. European Respiratory Journal, 2015, 46, 1202-1205.	3.1	11
115	Hepatitis B vaccination for people who inject drugs. Lancet, The, 2015, 385, 115.	6.3	2
116	Hippocampal glutamate is increased and associated with risky drinking in young adults with major depression. Journal of Affective Disorders, 2015, 186, 95-98.	2.0	25
117	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 2015, 26, 1094-1102.	1.6	18
118	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 2015, 26, 976-983.	1.6	44
119	The Clinical and Theoretical Basis for Integrated Cognitive Behavioral Treatment of Comorbid Social Anxiety and Alcohol Use Disorders. Cognitive and Behavioral Practice, 2015, 22, 504-521.	0.9	22
120	An overview of the patterns of prescription opioid use, costs and related harms in <scp>A</scp> ustralia. British Journal of Clinical Pharmacology, 2014, 78, 1159-1166.	1.1	172
121	Overview of Substance Use and Treatment from Australia. Substance Abuse, 2014, 35, 304-308.	1.1	8
122	Quantitation of fibroblast activation protein (FAP)â€specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio, 2014, 4, 43-54.	1.0	89
123	The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: A multisite randomized controlled trial Journal of Consulting and Clinical Psychology, 2014, 82, 130-140.	1.6	27
124	A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners. PLoS ONE, 2014, 9, e87564.	1.1	38
125	Osteopontin is an important mediator of alcoholic liver disease <i>via</i> hepatic stellate cell activation. World Journal of Gastroenterology, 2014, 20, 13088.	1.4	44
126	A novel mechanism of ovel mechanism of alcohol-induced hepatic stellate cell activation via secreted phosphoprotein 1 pathway. Journal of Clinical and Experimental Hepatology, 2013, 3, S22.	0.4	0

#	Article	IF	CITATIONS
127	A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine, 2013, 57, 297-303.	1.6	54
128	Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. International Journal of Drug Policy, 2013, 24, 326-332.	1.6	15
129	Secreted phosphoprotein 1 in chronic liver injury. Journal of Clinical and Experimental Hepatology, 2013, 3, S51-S52.	0.4	0
130	Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary Perinatal and Family Drug Health Service. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2013, 53, n/a-n/a.	0.4	7
131	Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Australian and New Zealand Journal of Public Health, 2013, 37, 311-315.	0.8	10
132	Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment, 2012, 43, 440-445.	1.5	28
133	Unplanned pregnancy and contraceptive use in women attending drug treatment services. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 146-150.	0.4	85
134	Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. Journal of Urban Health, 2012, 89, 769-778.	1.8	13
135	Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Substance Abuse and Rehabilitation, 2012, 3, 43.	1.6	3
136	Opportunistic and continuing health care for injecting drug users from a nurseâ€run needle syringe programâ€based primary healthâ€care clinic. Drug and Alcohol Review, 2012, 31, 114-115.	1.1	7
137	Effect of pegylated interferonâ€Î±â€2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 957-965.	1.4	38
138	Individual versus teamâ€based caseâ€management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 2012, 31, 499-506.	1.1	7
139	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology, 2011, 55, 76-85.	1.8	53
140	Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Australian Journal of Primary Health, 2011, 17, 10.	0.4	21
141	Pathogenesis of alcoholâ€induced liver disease: Classical concepts and recent advances. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1089-1105.	1.4	138
142	A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. Australian and New Zealand Journal of Public Health, 2011, 35, 294-295.	0.8	5
143	Training in Addiction Medicine in Australia. Substance Abuse, 2011, 32, 115-119.	1.1	7
144	Problem drinking - detection and assessment in general practice. Australian Family Physician, 2011, 40, 570-4.	0.5	2

#	Article	IF	CITATIONS
145	Problem drinkingmanagement in general practice. Australian Family Physician, 2011, 40, 576-82.	0.5	Ο
146	Incidence and risk for acute hepatitis C infection during imprisonment in Australia. European Journal of Epidemiology, 2010, 25, 143-148.	2.5	74
147	Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology, 2010, 51, 1463-1465.	3.6	26
148	Alcohol, Signaling, and ECM Turnover. Alcoholism: Clinical and Experimental Research, 2010, 34, 4-18.	1.4	33
149	The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 2010, 105, 329-334.	1.7	20
150	Prevalence and correlates of DSMâ€₩ alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. Addiction, 2010, 105, 2085-2094.	1.7	203
151	Forming a national multicentre collaboration to conduct clinical trials: Increasing highâ€quality research in the drug and alcohol field. Drug and Alcohol Review, 2010, 29, 469-474.	1.1	6
152	Some new directions for research on psychological interventions for comorbid anxiety and substance use disorders. Drug and Alcohol Review, 2010, 29, 518-524.	1.1	31
153	Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Medical Journal of Australia, 2010, 192, 496-500.	0.8	43
154	Clinical Predictors of Outcome from an Australian Pharmacological Relapse Prevention Trial. Alcohol and Alcoholism, 2010, 45, 520-526.	0.9	9
155	Expectancy in Double-Blind Placebo-Controlled Trials: An Example from Alcohol Dependence. Psychotherapy and Psychosomatics, 2009, 78, 167-171.	4.0	29
156	Charles S. Lieber, 1931-2009. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 941-942.	1.4	1
157	Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. Drug and Alcohol Review, 2009, 28, 222-229.	1.1	9
158	Understanding and Treating Patients With Alcoholic Cirrhosis: An Update. Alcoholism: Clinical and Experimental Research, 2009, 33, 1136-1144.	1.4	25
159	Management of injecting drug users admitted to hospital. Lancet, The, 2009, 374, 1284-1293.	6.3	99
160	Criminal Justice And Addiction Treatment: Best Practices in Addiction Treatment In the Criminal Justice System. Canadian Journal of Addiction, 2009, 1, 18.	0.2	0
161	Inflammation and Repair in Viral Hepatitis C. Digestive Diseases and Sciences, 2008, 53, 1468-1487.	1.1	31
162	The influence of alcohol and tobacco use in orthopaedic inpatients on complications of surgery. Drug and Alcohol Review, 2008, 27, 55-64.	1.1	26

#	Article	IF	CITATIONS
163	Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. Drug and Alcohol Review, 2008, 27, 115-122.	1.1	33
164	Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. Addiction, 2008, 103, 953-959.	1.7	57
165	Down-regulation of liver Gall²1, 4GlcNAc α2, 6-sialyltransferase gene by ethanol significantly correlates with alcoholic steatosis in humans. Metabolism: Clinical and Experimental, 2008, 57, 1663-1668.	1.5	22
166	Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease. Journal of Hepatology, 2008, 48, 614-627.	1.8	48
167	Unplanned admissions to two Sydney public hospitals after naltrexone implants. Medical Journal of Australia, 2008, 188, 441-444.	0.8	23
168	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, The, 2007, 370, 1915-1922.	6.3	611
169	"l'll never touch it again, doctor!―— harmful drinking after liver transplantation. Hepatology, 2007, 46, 1302-1304.	3.6	5
170	Transmission of hepatitis C virus by needle-stick injury in community settings. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1882-1885.	1.4	17
171	Detection of and intervention for excessive alcohol and tobacco use among adult hospital in-patients. Drug and Alcohol Review, 2007, 26, 127-133.	1.1	24
172	Pre-operative screening for excessive alcohol consumption among patients scheduled for elective surgery. Drug and Alcohol Review, 2007, 26, 119-125.	1.1	22
173	Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Drug and Alcohol Review, 2007, 26, 231-239.	1.1	30
174	Intrahepatic gene expression in human alcoholic hepatitis. Journal of Hepatology, 2006, 45, 306-320.	1.8	65
175	Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction, 2006, 101, 1451-1462.	1.7	143
176	Challenge for doctors and policy makers. BMJ: British Medical Journal, 2006, 332, 277.2-278.	2.4	0
177	THE EFFECTIVENESS OF A TAILORED INTERVENTION FOR EXCESSIVE ALCOHOL CONSUMPTION PRIOR TO ELECTIVE SURGERY. Alcohol and Alcoholism, 2006, 41, 643-649.	0.9	37
178	PREDICTORS OF RELAPSE TO HARMFUL ALCOHOL AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Alcohol and Alcoholism, 2006, 41, 278-283.	0.9	113
179	The medical complications of heroin use. Current Opinion in Psychiatry, 2005, 18, 257-263.	3.1	13
180	The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial Journal of Studies on Alcohol and Drugs, 2005, 66, 833-841.	2.4	31

#	Article	IF	CITATIONS
181	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. Journal of Infectious Diseases, 2004, 189, 1846-1855.	1.9	147
182	Genetic disorders in pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 939-939.	1.4	0
183	The Treatment of Drinking Problems: a Guide for the Helping Professions. Addiction, 2004, 99, 135-135.	1.7	0
184	Risk Factors for Hepatitis C Infection and Perception of Antibody Status among Male Prison Inmates in the Hepatitis C Incidence and Transmission in Prisons Study Cohort, Australia. Journal of Urban Health, 2004, 81, 448-452.	1.8	21
185	Non-Oxidative Metabolism of Ethanol by Rat Pancreatic Acini. Pancreatology, 2004, 4, 82-89.	0.5	45
186	General practitioners' diagnostic skills and referral practices in managing patients with drug and alcohol-related health problems: implications for medical training and education programmes. Drug and Alcohol Review, 2003, 22, 417-424.	1.1	34
187	Quality of life of women living with hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1329-1331.	1.4	2
188	Pathogenesis and management of alcoholic hepatitis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1332-1344.	1.4	61
189	Gene Expression Profiling of Alcoholic Liver Disease in the Baboon (Papio hamadryas) and Human Liver. American Journal of Pathology, 2003, 163, 2303-2317.	1.9	78
190	SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. Journal of Proteomics, 2003, 55, 53-66.	2.4	61
191	NSW Alcohol Summit: getting a better grip on our favourite drug. Medical Journal of Australia, 2003, 179, 521-522.	0.8	0
192	Antioxidants status and physical fitness in seniors aerobically trained and supplemented with a multivitamin drink. Forum of Nutrition, 2003, 56, 261-2.	3.7	1
193	Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Medical Journal of Australia, 2001, 174, 183-184.	0.8	57
194	Alcohol and the Pancreas. Alcoholism: Clinical and Experimental Research, 2001, 25, 244S-250S.	1.4	13
195	Alcohol and the pancreas. Alcoholism: Clinical and Experimental Research, 2001, 25, 244S-250S.	1.4	4
196	Metabolism of Alcohol by the Human Stomach. Alcoholism: Clinical and Experimental Research, 2000, 24, 407-408.	1.4	14
197	Transmission of hepatitis C within Australian prisons. Medical Journal of Australia, 1999, 171, 31-33.	0.8	51
198	Activation of Pancreatic Stellate Cells in Human and Experimental Pancreatic Fibrosis. American Journal of Pathology, 1999, 155, 1087-1095.	1.9	382

#	Article	IF	CITATIONS
199	Alcohol and the pancreas. Addiction Biology, 1998, 3, 137-150.	1.4	23
200	Cystic fibrosis genotypes and alcoholic pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 496-499.	1.4	57
201	Metabolism of ethanol by rat pancreatic acinar cells. Translational Research, 1998, 132, 294-302.	2.4	87
202	CLINICAL UPDATE: Management of acute pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 189-197.	1.4	9
203	Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Life Sciences, 1996, 58, 485-492.	2.0	16
204	Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma. New England Journal of Medicine, 1996, 334, 231-238.	13.9	295
205	Gastric metabolism of ethanol in Syrian golden hamster. Digestive Diseases and Sciences, 1995, 40, 2712-2716.	1.1	8
206	Relationship between hepatitis C virus subtypes and clinical features of liver disease seen in alcoholics. Journal of Hepatology, 1995, 22, 130-134.	1.8	15
207	Spontaneously Occurring Antibodies to Parathyroid Hormone*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1744-1749.	1.8	10
208	Management of alcohol and other drug issues in Special Health Accommodation during the <scp>COVID</scp> â€19 Delta variant outbreak in Sydney, 2021. Drug and Alcohol Review, 0, , .	1.1	1